Daunorubicin is named as a drug or biological intervention in 12 clinical trials in our China, USA, UK and Ireland trial registers, 9 of which are recruiting. Lead sponsors include Institute of Hematology & Blood Diseases Hospital, China (4), Kura Oncology, Inc. (2) and University Hospital Muenster (1). Registered phases: Phase 3, Phase 2, Phase 1, Phase 2/3 and Not applicable. Conditions studied include Acute Myeloid Leukemia; Lymphoblastic Lymphoma, Childhood; Leukemia, Myeloid, Acute.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Acute Myeloid Leukemia | 4 |
| Lymphoblastic Lymphoma, Childhood | 1 |
| Leukemia, Myeloid, Acute | 1 |
| Acute Myeloid Leukemia (AML) | 1 |
| Mixed Lineage Leukemia Gene Mutation | 1 |
| Refractory AML | 1 |
| AML With Mutated NPM1 | 1 |
| NPM1 Mutation | 1 |
| IDH1 Mutation | 1 |
| IDH2 Mutation | 1 |
| Acute Leukemia of Ambiguous Lineage | 1 |
| Lisaftoclax | 1 |
| AML, Adult | 1 |
| AML | 1 |
| Relapsed or Refractory Acute Myeloid Leukemia | 1 |
| AML (Acute Myelogenous Leukemia) | 1 |
| Lead sponsor | Trials |
|---|---|
| Institute of Hematology & Blood Diseases Hospital, China | 4 |
| Kura Oncology, Inc. | 2 |
| University Hospital Muenster | 1 |
| Janssen Research & Development, LLC | 1 |
| Shen yang | 1 |
| First Affiliated Hospital of Zhejiang University | 1 |
| Shanxi Bethune Hospital | 1 |
| Sichuan Baili Pharmaceutical Co., Ltd. | 1 |
| Register | Daunorubicin trials |
|---|---|
| Clinical trials in China | 9 |
| Clinical trials in USA | 3 |
| Clinical trials in UK | 2 |
| Clinical trials in Ireland | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Daunorubicin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Daunorubicin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.